Publications by authors named "Massimo Morfini"

Claim this Profile
P
Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.
Massimo Morfini, Flora Peyvandi, Maria Elisa Mancuso, Emanuela Marchesini, Annarita Tagliaferri

J Clin Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Prophylaxis with myPKFiT: A Real-World Cost-Effectiveness Analysis in Haemophilia A Patients.
Ippazio Cosimo Antonazzo, Paolo Angelo Cortesi, Ezio Zanon, Samantha Pasca, Massimo Morfini

Medicina (Kaunas)· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers.
Ezio Zanon, Raimondo De Cristofaro, Massimo Franchini, Massimo Morfini, Gianfranco Pasut

Blood Transfus· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Managing Relevant Clinical Conditions of Hemophilia A/B Patients.
Massimo Morfini, Jacopo Agnelli Giacchiello, Erminia Baldacci, Christian Carulli, Giancarlo Castaman

Hematol Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors.
Barbara Lunghi, Massimo Morfini, Nicola Martinelli, Alessio Branchini, Silvia Linari

Haemophilia· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A.
Barbara Lunghi, Massimo Morfini, Nicola Martinelli, Dario Balestra, Silvia Linari

Thromb Haemost· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.
Alessio Branchini, Massimo Morfini, Barbara Lunghi, Donata Belvini, Paolo Radossi

J Thromb Haemost· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of rs868875 G-Carriership and O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients.
Barbara Lunghi, Massimo Morfini, Nicola Martinelli, Silvia Linari, Giancarlo Castaman

J Clin Med· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects.
Victor S Blanchette, Laura Zunino, Viviane Grassmann, Chris Barnes, Manuel D Carcao, Massimo Morfini

Thromb Haemost· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in the Treatment of Hemophilia: A Review.
Emanuela Marchesini, Massimo Morfini, Leonard Valentino

Biologics· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors.
Victor Jiménez-Yuste, Günter Auerswald, Gary Benson, Gerry Dolan, Cedric Hermans, Massimo Morfini

Haemophilia· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
Joint replacement for the management of haemophilic arthropathy in patients with inhibitors: A long-term experience at a single Haemophilia centre.
Christian Carulli, Matteo Innocenti, Silvia Linari, Massimo Morfini, Giancarlo Castaman

Haemophilia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic characteristics of the triple inactivated plasma-derived Kedrion FIX concentrate: data from the KB037 clinical trial.
Massimo Morfini, Chiara Guarnieri, Roberta Macchia, Manuela Scarpellini, Prasad Mathew

Data Brief· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study.
Alberto Tosetto, Zahra Badiee, Mohammad-Reza Baghaipour, Luciano Baronciani, Javier Battle, Massimo Morfini

J Thromb Haemost· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The availability of new drugs for hemophilia treatment.
Massimo Morfini, Emanuela Marchesini

Expert Rev Clin Pharmacol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
Alice S van Velzen, Corien L Eckhardt, Marjolein Peters, Johannes Oldenburg, Marjon Cnossen, Massimo Morfini

Br J Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
Giancarlo Castaman, Cristina Santoro, Antonio Coppola, Maria E Mancuso, Rita C Santoro, Massimo Morfini

Blood Transfus· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.
Giancarlo Castaman, Alessandra Borchiellini, Elena Santagostino, Giuseppe Tagariello, Margit Serban, Massimo Morfini

Haemophilia· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
Massimo Morfini, Albert Farrugia

Expert Rev Hematol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates.
Barbara Lunghi, Francesco Bernardi, Nicola Martinelli, Sabrina Frusconi, Alessio Branchini, Massimo Morfini

J Thromb Haemost· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
Manuel D Carcao, Pierre Chelle, Emily Clarke, Lussia Kim, Laura Tiseo, Massimo Morfini

J Thromb Haemost· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
Rolf Ljung, Guenter Auerswald, Gary Benson, Gerry Dolan, Anne Duffy, Massimo Morfini

Eur J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of recombinant coagulation factors in treating hemophilia.
Massimo Morfini, Carlo Antonio Paolo Rapisarda

Expert Opin Drug Saf· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A.
Giovanni Di Minno, Elena Santagostino, Massimo Morfini, Cosimo Ettorre, Dorina Cultrera

Patient Prefer Adherence· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical aspects of extended half-life products for the treatment of haemophilia.
Thierry Lambert, Gary Benson, Gerry Dolan, Cedric Hermans, Victor Jiménez-Yuste, Massimo Morfini

Ther Adv Hematol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis